The molecular mechanisms by which varicella-zoster virus (VZV) causes a latent infection in human trigeminal and spinal ganglia are not well understood. It is known that VZV establishes latency in ganglia following the primary infection causing varicella (chickenpox), and that the virus may reactivate after years of dormancy to produce herpes zoster (shingles). Two key issues have been the cell-type localization of latent VZV in human ganglia, and the nature and extent of VZV gene expression during latency. Although the cell specificity of latent VZV has been controversial for almost a decade, it is now widely accepted that the virus is mainly latent in neuronal cells, with only a small proportion of non-neuronal cells infected. All of the studies carried out so far have indicated that VZV gene expression is highly restricted during ganglionic latency. Although at least four VZV genes have been identified as being expressed, the possibility that latent gene expression is significantly greater than this cannot yet be excluded. There is also evidence for VZV gene-encoded proteins being expressed during latency, although the precise extent of this is unclear. Advances in this difficult field may be expected to arise from both newly developed molecular technology and more refined animal models of VZV latency. Journal of NeuroVirology (2002) 8(suppl. 2), 80-84.
Introduction
Varicella-zoster virus (VZV) is a human herpesvirus, which is the causative agent of varicella (also known as chickenpox). Following this primary infection, which generally, but not always, occurs in children, VZV is transported by sensory nerve fibers to the trigeminal ganglia (TG) and the dorsal root ganglia (DRG) where the virus establishes a latent infection (Gilden et al, 2000b) . After a variable interval, which may be decades, the virus may reactivate, either spon-taneously or following one or a number of triggering factors, to produce herpes zoster (also known as shingles), which is a painful skin eruption that usually affects an entire dermatomal region (Gilden et al, 2000b) . Factors that increase the possibility of VZV reactivations include increasing age and the coexistence of a state of immunosuppression. VZV reactivations may be followed by a number of neurological complications, including postherpetic neuralgia, which is a major cause of morbidity, and a variety of other central nervous system (CNS) conditions, including small and large vessel vasculopathy, segmental weakness, and cranial nerve palsies (Gilden et al, 2000a) .
The burden of VZV-associated disease is considerable and much greater than was previously thought. The importance of CNS VZV infections was recently highlighted by a study from Finland in which VZV was identified as being the causal agent in no less than 29% of all probable or confirmed etiological agents of encephalitis, meningitis, and myelitis in a total of 3231 patients with suspected CNS viral disease (Koskiniemi et al, 2001) . Most hospital admissions of VZV infections in a recent study in Scotland were for trigeminal zoster, with a length of stay ranging from 1 to 70 days (median 11 days), and it was predicted that the incidence of zoster would increase as the population ages (Torrens et al, 1998) . In the USA, a previous estimate of about 300,000 cases of zoster annually (Weller, 1992 ) is now almost certainly an underestimate, especially because VZV reactivates in about 15% of individuals (Cohen et al, 1999) .
Details of the VZV genome will not be given here and have been described elsewhere (Ostrove, 1990) . Essentially, the VZV genome contains doublestranded DNA, with a size just under 125 kb, with 71 predicted open reading frames (ORFs), of which about 65 have known homologs in herpes simplex virus type 1 (HSV-1) (Cohen et al, 1999; Ostrove, 1990) . The genome has been shown to comprise a unique long (U L ) segment and a unique short (U S ) segment, which are covalently linked, and these segments are both flanked by terminal and internal repeat regions (Cohen et al, 1999; Ostrove, 1990) . Our knowledge of VZV infections has tended to lag behind that of HSV-1, due primarily to the considerable difficulty in working with VZV because of its very cell-associated nature, making growth of the virus to high titer difficult, and the fact that it only grows in human or primate cells. The VZV genome contains putative immediate-early, early, and late genes, and viral gene expression during acute lytic infection appears to be sequentially regulated, as is the case with HSV-1 (Cohen et al, 1999) .
VZV ganglionic latency
The ultimate aim of VZV latency studies is to understand the molecular mechanisms of the establishment and maintenance of ganglionic latency, and of viral reactivation, with the long-term goal of devising more effective measures to treat, if not prevent, VZV-associated neurological disease. Unfortunately, the only method of investigating VZV latency in humans at present is to study postmortem TG and DRG, in which mechanistic studies are not feasible (Gilden et al, 2000b) . Moreover, it is not possible to exclude the possibility that a degree of viral reactivation may have already occurred at the time of death or removal of tissues at autopsy. This restriction is compounded by the absence of very good animal models of VZV latency and reactivation, although there have been some recent promising advances in this area.
It is known from careful and detailed polymerase chain reaction (PCR)-based studies that almost 90% of normal individuals harbor latent VZV DNA in their TG (Mahalingam et al, 1990) . Correct identification of the ganglionic cell type in which latent VZV resides is important in that it should enhance our understanding of the latency process. Although one might strongly suspect intuitively that VZV may mirror the neuronal specificity of latent HSV-1 (Steiner and Kennedy, 1993 ), a compelling case has also been made for the conceptual advantage in pathogenetic terms of VZV residing in non-neuronal satellite cells (Meier and Straus, 1992) . Thus Meier and Straus (1992) argued that non-neuronally located VZV, when reactivated, may proliferate extensively, with spread to both neuronal and non-neuronal cells, and that this might help explain the extensive dermatomal distribution of herpes zoster, in contrast to the limited cutaneous lesions of reactivated HSV-1. However, early studies in human TG using in situ hybridization (ISH) reported that latent VZV was located in neurons (Hyman et al, 1983) , findings that were later confirmed by Gilden and colleagues (1987) . On the other hand, two subsequent studies from Straus and colleagues using ISH strongly suggested that latent VZV resided in non-neuronal satellite cells and not neurons (Croen et al, 1988; Meier et al, 1993) . In the 'third phase' of the investigation of this issue, Lungu et al (1995) , using ISH, found that VZV was located in a high percentage of both neurons and satellite cells. In the most extensive study to date of this issue, Kennedy et al (1998) used ISH and in situ PCR amplification on a large number of TG (including coded samples obtained from both the Straus and Gilden laboratories) to show unambiguously that latent VZV was located predominantly in neurons, with only occasional nonneuronal satellite cells infected (Figure 1) . A subsequent study confirmed these findings in human DRG, in which it was also shown that more than one region 
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of the viral genome was present in neurons during latency . A neuronal localization of latent VZV was also demonstrated by LaGuardia et al (1999) by analysis of dissociated TG neuronal and non-neuronal cells, thus providing an elegant confirmation of the neuronal site of viral latency (Mahalingam et al, 1999) .
The second key issue in VZV latency is the extent of viral gene expression during ganglionic latency (Kennedy, 2002) . This is an important question to address for two reasons. First, this should theoretically enhance our understanding of the latency process because the functions of so many of the VZV genes are already known or inferred through homology with HSV-1. However, there are two caveats that should be added here, namely, that the inferred homologies may not all be completely correct as has been demonstrated for gene 21 (Cohrs et al, 2002) , and also that it is very difficult to prove the biological function of a known expressed VZV gene during latency because mechanistic studies are not possible in human ganglia. Second, viral genes that are expressed during latency may be targeted for antiviral strategies. But caveats to be added in this context include the problem of selection of particular gene products out of possibly multiple expressed genes, and also the mode of delivery of potential therapies, e.g., antisense oligonucleotides. In addition, there is the problem of deciding whether to use such therapies to prevent the viral reactivation process, e.g., immunization protocols against expressed viral proteins, or to attempt to limit reactivation once it has started.
There have been several published studies of latent VZV gene expression using a variety of different techniques on pooled and individual human ganglia, including Northern blot analysis, ISH, and cDNA library construction (Kennedy, 2002) . Most studies have reported the presence of RNA for VZV genes 21, 29, 62, and 63 (Cohrs et al, 1994 (Cohrs et al, , 1995 Kennedy et al, 2000; Meier et al, 1993) , with conflicting results for the presence of RNA for gene 4, which has been reported by some (Croen et al, 1988; Kennedy et al, 2000) but not other (Meier et al, 1993) groups. In our own studies using ISH, RNA for VZV genes 21, 29, 62, and 63 were the most frequently detected in TG from both normal and human immunodeficiency virus (HIV)-infected individuals, and RNA for both genes 4 and 18 were also detected, but at a lower frequency (Kennedy et al, 2000) (Figure 2) . The most frequently detected VZV transcript in this study, and also a recent detailed study using real-time PCR (Cohrs et al, 2000) , was that corresponding to VZV gene 63. The VZV RNA signals were again localized predominantly in neurons, with only occasional satellite cells being positive. There is now a consensus that VZV gene 63-encoded protein is present in a significant proportion of TG (Kennedy, 2002; Mahalingam et al, 1996) , up to 25% in a recent study (Kennedy et al, 2000) . There has also been a report by Lungu et al (1998) that demonstrated the presence of proteins encoded by VZV genes 4, 21, 29, 62, and 63 in the cytoplasm of neurons and non-neuronal cells in latently infected TG. These studies await confirmation but are very important as they indicate possible immunization targets for preventing VZV-associated neurological disease. Recent studies on a rat model of VZV latency have also strongly suggested that VZV gene expression is limited to these small number of
